- Advertisement -
- Advertisement -
- Advertisement -

Find a job

Subscribe for free

All things Pharma

Boston Scientific expands PAD portfolio

 Boston Scientific has acquired two new products to add to its portfolio of devices for lower extremity peripheral artery disease.

A re-entry catheter was acquired in November 2010 from S.I. Therapies, Ltd., and now the company will add an intraluminal CTO crossing device through its acquisition of Sunnyvale, ReVascular Therapeutics, Inc.

Both devices treat peripheral chronic total occlusions (CTOs), which typically cannot be treated with standard endovascular devices such as guidewires and other catheter-based technologies.

Worldwide launches of the devices are expected later this year.

“These acquisitions demonstrate our continued strategic execution of realigning and strengthening our portfolio in areas with high-growth potential,” said Ray Elliott, President and CEO of Boston Scientific (pictured).

“Our Priority Growth Initiatives include peripheral vascular disease, in which a significant number of patients remain undiagnosed or untreated. Addressing these challenges through use of less-invasive devices could greatly improve the care these patients receive.”

“Having used both devices, I am impressed with their simplicity and effectiveness,” added Dierk Scheinert, MD, Heart Center Leipzig. “Access to these technologies will greatly enhance therapeutic options and provide physicians with new, intuitive solutions for treating challenging CTOs.”

- Advertisement -


- Advertisement -



Sign up to receive our digital newsletter, for all the essential headlines, Jobs of the Week and thought-provoking features.

Claim my free subscription